Expression of alpha(v)beta6 integrin in oral leukoplakia.
The distribution of alpha(v)beta6 integrin was examined in oral leukoplakia, lichen planus and squamous cell carcinomas using immunohistochemistry. Controls included oral mucosal wounds, chronically inflamed and normal oral mucosa. Integrins beta1, beta3, beta4, beta5, fibronectin and tenascin were also studied. The integrin alpha(v)beta6 was highly expressed throughout the whole lesion of 90% of the squamous cell carcinomas but was not present in any of the normal specimens. alpha(v)beta6 integrin was also expressed in 41% of the leukoplakia specimens, and 85% of the lichen planus samples, but in none of the tissues with inflammatory hyperplasia or chronic inflammation. The expression of beta1 integrins was localized in the basal layer, and that of the beta4 at the cell surface facing the basement membrane of all specimens. The integrins beta3 and beta5 were absent from all normal and leukoplakia specimens. Fibronectin and tenascin were present in the connective tissue underneath the epithelium of all the sections, and their expression was similar in both alpha(v)beta6-positive and alpha(v)beta6-negative tissues. A group of 28 leukoplakia patients were followed 1-4 years after first diagnosis. In this group, initially alpha(v)beta6 integrin-positive leukoplakia specimens had high tendency for disease progression while alpha(v)beta6-negative specimens did not progress. These results suggest that the expression of alpha(v)beta6 integrin could be associated in the malignant transformation of oral leukoplakias.
Hamidi
S
S
Faculty of Dentistry, University of British Columbia, Vancouver, Canada.
Salo
T
T
Kainulainen
T
T
Epstein
J
J
Lerner
K
K
Larjava
H
H
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D000951:Antigens, Neoplasm; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D006965:Hyperplasia; D007249:Inflammation; D039641:Integrin beta Chains; D019012:Integrin beta1 / Q000032:analysis; D039661:Integrin beta3; D039663:Integrin beta4; D016023:Integrins / Q000032:analysis*; D007972:Leukoplakia, Oral / Q000473:pathology*; D008010:Lichen Planus / Q000473:pathology; D009061:Mouth Mucosa / Q000166:cytology / Q000293:injuries / Q000473:pathology; D009062:Mouth Neoplasms / Q000473:pathology*; D010980:Platelet Membrane Glycoproteins / Q000032:analysis; D012907:Smoking; D019063:Tenascin / Q000032:analysis
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D005353:Fibronectins; D039641:Integrin beta Chains; D019012:Integrin beta1; D039661:Integrin beta3; D039663:Integrin beta4; D016023:Integrins; D010980:Platelet Membrane Glycoproteins; D019063:Tenascin; C073878:integrin alphavbeta6; C084344:integrin beta5